TOP2A and colorectal carcinoma: In RNA-Seq and KEGG pathway analyses, we found that TOP2A was highly expressed in CRC cells and significantly downregulated by CX258 treatments (Figure 4E,F), an outcome suggesting a potential mechanism of action for CX258.